Momelotinib Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Video

Dr Aaron Gerds discusses the long term safety data of momelotinib, a JAK1/JAK2 inhibitor, in patients with myelofibrosis.

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Related Content